Wave Life Sciences - WVE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.17
  • Forecasted Upside: 79.53%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$6.22
▲ +0.13 (2.13%)

This chart shows the closing price for WVE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Wave Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WVE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WVE

Analyst Price Target is $11.17
▲ +79.53% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Wave Life Sciences in the last 3 months. The average price target is $11.17, with a high forecast of $17.00 and a low forecast of $5.00. The average price target represents a 79.53% upside from the last price of $6.22.

This chart shows the closing price for WVE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 polled investment analysts is to moderate buy stock in Wave Life Sciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024Wells Fargo & CompanyInitiated CoverageOverweight$11.00Low
4/1/2024Truist FinancialReiterated RatingBuy ➝ Buy$17.00Low
3/7/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$5.00Low
3/7/2024HC WainwrightBoost TargetBuy ➝ Buy$8.00 ➝ $15.00Low
12/19/2023Leerink PartnrsUpgradeMarket Perform ➝ OutperformLow
12/19/2023SVB LeerinkUpgradeMarket Perform ➝ Outperform$5.00 ➝ $12.00Low
8/4/2023Leerink PartnrsReiterated RatingMarket PerformLow
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$8.00Low
7/5/2023Raymond JamesInitiated CoverageOutperform$7.00Low
5/24/2023MizuhoLower Target$13.00 ➝ $10.00Low
5/23/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$7.00 ➝ $5.00Low
4/14/2023MizuhoReiterated RatingBuy$13.00Low
3/23/2023HC WainwrightReiterated RatingBuy$8.00Low
12/14/2022SVB LeerinkBoost TargetMarket Perform$2.00 ➝ $7.00Low
11/11/2022Royal Bank of CanadaLower TargetSector Perform$8.00 ➝ $5.00Low
10/24/2022SVB LeerinkReiterated RatingMarket PerformLow
5/13/2022HC WainwrightLower Target$10.00 ➝ $8.00High
3/4/2022HC WainwrightReiterated RatingBuy$10.00Medium
9/29/2021HC WainwrightReiterated RatingBuy$10.00High
5/19/2021MizuhoBoost TargetBuy$7.00 ➝ $8.00Low
3/30/2021Truist FinancialLower Target$27.00 ➝ $17.00High
3/30/2021SVB LeerinkLower TargetMarket Perform$10.00 ➝ $7.00High
3/30/2021MizuhoLower TargetBuy$21.00 ➝ $7.00High
3/30/2021Royal Bank of CanadaLower TargetSector Perform$13.00 ➝ $8.00High
3/11/2021MizuhoBoost TargetBuy$19.00 ➝ $21.00Medium
3/7/2021Royal Bank of CanadaReiterated RatingHoldHigh
3/7/2021SVB LeerinkReiterated RatingHold$10.00High
12/15/2020HC WainwrightReiterated RatingBuy$20.00Low
11/20/2020MizuhoLower TargetBuy$21.00 ➝ $19.00Low
10/22/2020Royal Bank of CanadaInitiated CoverageSector Perform$13.00High
9/22/2020Truist FinancialBoost Target$20.00 ➝ $27.00Low
6/7/2020MizuhoReiterated RatingBuy$21.00High
1/2/2020HC WainwrightLower TargetBuy$33.00 ➝ $20.00Low
12/31/2019SunTrust BanksReiterated RatingBuy$20.00Medium
12/31/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$33.00 ➝ $10.00High
12/30/2019MizuhoInitiated CoverageBuy$65.00Low
12/17/2019SunTrust BanksLower TargetBuy$39.00 ➝ $27.00High
12/17/2019GuggenheimLower TargetBuy$43.00 ➝ $25.00High
12/16/2019MizuhoInitiated CoverageBuy$65.00High
12/16/2019CowenReiterated RatingHoldHigh
11/21/2019MizuhoInitiated CoverageBuy$65.00Medium
11/1/2019GuggenheimInitiated CoverageBuy$43.00High
10/9/2019HC WainwrightSet TargetBuy$33.00Low
9/25/2019MizuhoReiterated RatingBuyLow
7/31/2019HC WainwrightReiterated RatingBuyHigh
7/30/2019CowenReiterated RatingHoldHigh
7/22/2019MizuhoReiterated RatingBuy$65.00High
7/15/2019CowenInitiated CoverageMarket Perform ➝ Market PerformMedium
6/29/2019MizuhoSet TargetBuy$65.00High
6/28/2019HC WainwrightSet TargetBuy$33.00High
(Data available from 5/25/2019 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/28/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
11/27/2023
  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/26/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/25/2024
  • 10 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/26/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 5 very positive mentions
  • 19 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/25/2024

Current Sentiment

  • 5 very positive mentions
  • 19 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Wave Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $6.22
Low: $6.05
High: $6.29

50 Day Range

MA: $5.72
Low: $4.66
High: $6.44

52 Week Range

Now: $6.22
Low: $3.41
High: $7.67

Volume

313,793 shs

Average Volume

688,882 shs

Market Capitalization

$761.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Wave Life Sciences?

The following equities research analysts have issued stock ratings on Wave Life Sciences in the last twelve months: HC Wainwright, Leerink Partnrs, Raymond James, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for WVE.

What is the current price target for Wave Life Sciences?

6 Wall Street analysts have set twelve-month price targets for Wave Life Sciences in the last year. Their average twelve-month price target is $11.17, suggesting a possible upside of 79.5%. Truist Financial Co. has the highest price target set, predicting WVE will reach $17.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $5.00 for Wave Life Sciences in the next year.
View the latest price targets for WVE.

What is the current consensus analyst rating for Wave Life Sciences?

Wave Life Sciences currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for WVE.

What other companies compete with Wave Life Sciences?

How do I contact Wave Life Sciences' investor relations team?

Wave Life Sciences' physical mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company's listed phone number is (656) 236-3388 and its investor relations email address is [email protected]. The official website for Wave Life Sciences is www.wavelifesciences.com. Learn More about contacing Wave Life Sciences investor relations.